Skip to Main Content

Paper Details

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
Eur J Cancer
161
2014
Author NameAffiliation
Roberta FerraldeschiThe Royal Marsden NHS Foundation Trust, The Institute of Cancer Research
Gerhardt AttardThe Royal Marsden NHS Foundation Trust, The Institute of Cancer Research
Johann S de BonoThe Royal Marsden NHS Foundation Trust, The Institute of Cancer Research
  • 1 - 3

Datasets

Release 1.2